Novartis Acquires Regulus Therapeutics

This is a news story, published by Yahoo Finance, that relates primarily to Novartis AG news.

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

Novartis AG

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Regulus Joins Novartis news, Regulus Therapeutics news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Novartis

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

•

Health

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

Summary

Nutrition label

75% Informative

Novartis AG ( NYSE : NVS ) confirmed it had completed the acquisition of Regulus Therapeutics .

The acquisition marks a crucial step in the company’s effort to advance the clinical development of a potential first -in-class medicine for autosomal dominant polycystic kidney disease.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful